These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 36216697)
1. Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma. Thielen FW; Heine RJSD; Berg SVD; Ham RMTT; Groot CAU Cytotherapy; 2022 Dec; 24(12):1245-1258. PubMed ID: 36216697 [TBL] [Abstract][Full Text] [Related]
2. Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios. Broekhoff TF; Sweegers CCG; Krijkamp EM; Mantel-Teeuwisse AK; Leufkens HGM; Goettsch WG; Vreman RA Value Health; 2021 Jun; 24(6):759-769. PubMed ID: 34119073 [TBL] [Abstract][Full Text] [Related]
3. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629 [TBL] [Abstract][Full Text] [Related]
4. Streamlined data-gathering techniques to estimate the price and affordability of healthy and unhealthy diets under different pricing scenarios. Zorbas C; Lee A; Peeters A; Lewis M; Landrigan T; Backholer K Public Health Nutr; 2021 Jan; 24(1):1-11. PubMed ID: 32662385 [TBL] [Abstract][Full Text] [Related]
5. What is a fair price for a medicine? Establishing the main elements of a fair price based on the current policy debate. Roediger A; Schönbächler G; Brand H Public Health; 2024 Jun; 231():148-153. PubMed ID: 38692089 [TBL] [Abstract][Full Text] [Related]
6. Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020. Desai A; Scheckel C; Jensen CJ; Orme J; Williams C; Shah N; Leventakos K; Adjei AA JAMA Netw Open; 2022 Jan; 5(1):e2144923. PubMed ID: 35076701 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology. Saeed A; Saeed H; Saleem Z; Fang Y; Babar ZU PLoS One; 2019; 14(4):e0216122. PubMed ID: 31022276 [TBL] [Abstract][Full Text] [Related]
9. Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries. Palafox B; Patouillard E; Tougher S; Goodman C; Hanson K; Kleinschmidt I; Torres Rueda S; Kiefer S; O'Connell K; Zinsou C; Phok S; Akulayi L; Arogundade E; Buyungo P; Mpasela F; Poyer S; Chavasse D Health Policy Plan; 2016 Mar; 31(2):148-60. PubMed ID: 25944705 [TBL] [Abstract][Full Text] [Related]
10. Cost-Based Price Calculation of Mexiletine for Nondystrophic Myotonia. van den Berg S; van der Wel V; de Visser SJ; Stunnenberg BC; Timmers L; van der Ree MH; Postema PG; Hollak CEM Value Health; 2021 Jul; 24(7):925-929. PubMed ID: 34243835 [TBL] [Abstract][Full Text] [Related]
11. Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies. Ha SY; Kang DW; Jung HI; Lee EK; Park MH Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409788 [TBL] [Abstract][Full Text] [Related]
12. Uncertainty and risk: A framework for understanding pricing in online drug markets. Munksgaard R; Tzanetakis M Int J Drug Policy; 2022 Mar; 101():103535. PubMed ID: 34902806 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. Malone DC; Dean R; Arjunji R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Dabbous O J Mark Access Health Policy; 2019; 7(1):1601484. PubMed ID: 31105909 [No Abstract] [Full Text] [Related]
14. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966 [TBL] [Abstract][Full Text] [Related]
15. Comparative value-based pricing of an Ebola vaccine in resource-constrained countries based on cost-effectiveness analysis. Obeng-Kusi M; Erstad B; Roe DJ; Abraham I J Med Econ; 2022; 25(1):894-902. PubMed ID: 35748085 [TBL] [Abstract][Full Text] [Related]
16. Value-based differential pricing: efficient prices for drugs in a global context. Danzon P; Towse A; Mestre-Ferrandiz J Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269 [TBL] [Abstract][Full Text] [Related]
17. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020. Yıldız M; Osman E Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516 [TBL] [Abstract][Full Text] [Related]
18. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation. Stargardt T; Schreyögg J Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840 [TBL] [Abstract][Full Text] [Related]
19. [Pharmaceutical pricing; what is reasonable?]. Versteegh MM Ned Tijdschr Geneeskd; 2020 Aug; 164():. PubMed ID: 32940991 [TBL] [Abstract][Full Text] [Related]